{"doi":"10.1101/2021.09.17.21263758","title":"Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial","abstract":"BACKGROUND: Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease virus vaccine expressing the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It's being developed in Thailand, Vietnam, and Brazil; herein are initial results from Thailand. METHODS: This phase 1 stage of a randomised, dose-escalation, observer-blind, placebo-controlled, phase 1/2 trial was conducted at the Vaccine Trial Centre, Mahidol University (Bangkok). Healthy adults aged 18-59 years, non-pregnant and negative for SARS-CoV-2 antibodies were eligible. Participants were block randomised to receive one of six treatments by intramuscular injection twice, 28 days apart: 1 µg±CpG1018 (a toll-like receptor 9 agonist), 3 µg±CpG1018, 10 µg, or placebo. Participants and personnel assessing outcomes were masked to treatment. The primary outcomes were solicited and spontaneously reported adverse events (AEs) during 7 and 28 days after each vaccination, respectively. Secondary outcomes were immunogenicity measures (anti-S IgG and pseudotyped virus neutralisation). An interim analysis assessed safety at day 57 in treatment-exposed individuals and immunogenicity through day 43 per protocol. ClinicalTrials.gov ( NCT04764422 ). FINDINGS: Between March 20 and April 23, 2021, 377 individuals were screened and 210 were enrolled (35 per group); all received dose one; five missed dose two. The most common solicited AEs among vaccinees, all predominantly mild, were injection site pain (<63%), fatigue (<35%), headache (<32%), and myalgia (<32%). The proportion reporting a vaccine-related AE ranged from 5·7% to 17·1% among vaccine groups and was 2·9% in controls; there was no vaccine-related serious adverse event. The 10 µg formulation's immunogenicity ranked best, followed by 3 µg+CpG1018, 3 µg, 1 µg+CpG1018, and 1 µg formulations. On day 43, the geometric mean concentrations of 50% neutralising antibody ranged from 122·23 IU/mL (1 µg, 95% CI 86·40-172·91) to 474·35 IU/mL (10 µg, 95% CI 320·90-701·19), with 93·9% to 100% of vaccine groups attaining a ≥4-fold increase over baseline. INTERPRETATION: NDV-HXP-S had an acceptable safety profile and potent immunogenicity. The 3 µg and 3 µg+CpG1018 formulations advanced to phase 2. FUNDING: National Vaccine Institute (Thailand), National Research Council (Thailand), Bill & Melinda Gates Foundation, National Institutes of Health (USA).","journal":"medRxiv","year":2021,"id":214896,"datarank":0.4860061903230017,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.15642250372256872,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.15642250372256872,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":5,"citers_with_citation_signal":4,"citers_with_endowment":4,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9641,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT04764422"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":739754,"name":"Viravarn Luvira","orcid":"0000-0001-9270-3720","position":1,"is_corresponding":false},{"id":378078,"name":"Saranath Lawpoolsri","orcid":"0000-0003-4841-7924","position":2,"is_corresponding":false},{"id":809051,"name":"Sant Muangnoicharoen","orcid":"0000-0002-8236-8954","position":3,"is_corresponding":false},{"id":809615,"name":"Supitcha Kamolratanakul","orcid":null,"position":4,"is_corresponding":false},{"id":731147,"name":"Chaisith Sivakorn","orcid":"0000-0001-5662-1058","position":5,"is_corresponding":false},{"id":809616,"name":"Piengthong Narakorn","orcid":null,"position":6,"is_corresponding":false},{"id":809617,"name":"Somchaiya Surichan","orcid":null,"position":7,"is_corresponding":false},{"id":809618,"name":"Sumalee Prangpratanporn","orcid":null,"position":8,"is_corresponding":false},{"id":809619,"name":"Suttida Puksuriwong","orcid":null,"position":9,"is_corresponding":false},{"id":809620,"name":"Steven Lamola","orcid":null,"position":10,"is_corresponding":false},{"id":809052,"name":"Laina D. Mercer","orcid":"0000-0002-2517-8900","position":11,"is_corresponding":false},{"id":809053,"name":"Rama Raghunandan","orcid":"0000-0001-8254-0809","position":12,"is_corresponding":false},{"id":272522,"name":"Weina Sun","orcid":"0000-0002-2435-5047","position":13,"is_corresponding":false},{"id":272523,"name":"Yonghong Liu","orcid":"0000-0001-8327-3108","position":14,"is_corresponding":false},{"id":360832,"name":"Juan Manuel Carreño","orcid":"0000-0002-9039-9275","position":15,"is_corresponding":false},{"id":809621,"name":"Rami Scharf","orcid":null,"position":16,"is_corresponding":false},{"id":809054,"name":"Weerapong Phumratanaprapin","orcid":"0000-0001-5896-1961","position":17,"is_corresponding":false},{"id":104911,"name":"Fatima Amanat","orcid":"0000-0002-8029-8227","position":18,"is_corresponding":false},{"id":806081,"name":"Luc Gagnon","orcid":null,"position":19,"is_corresponding":false},{"id":87313,"name":"Ching‐Lin Hsieh","orcid":"0000-0002-3665-5717","position":20,"is_corresponding":false},{"id":809622,"name":"Ruangchai Kaweepornpoj","orcid":null,"position":21,"is_corresponding":false},{"id":809623,"name":"Sarwat Khan","orcid":null,"position":22,"is_corresponding":false},{"id":809055,"name":"Manjari Lal","orcid":"0000-0003-3574-9989","position":23,"is_corresponding":false},{"id":273276,"name":"Stephen McCroskery","orcid":null,"position":24,"is_corresponding":false},{"id":87312,"name":"Jason S. McLellan","orcid":"0000-0003-3991-542X","position":25,"is_corresponding":false},{"id":2386,"name":"Ignacio Mena","orcid":"0000-0001-5464-7086","position":26,"is_corresponding":false},{"id":809056,"name":"Marcia Meseck","orcid":"0000-0002-9527-6602","position":27,"is_corresponding":false},{"id":809624,"name":"Benjaluck Phonrat","orcid":null,"position":28,"is_corresponding":false},{"id":809625,"name":"Yupa Sabmee","orcid":null,"position":29,"is_corresponding":false},{"id":809626,"name":"Ratsamikorn Singchareon","orcid":null,"position":30,"is_corresponding":false},{"id":272524,"name":"Stefan Slamanig","orcid":"0000-0003-3694-6597","position":31,"is_corresponding":false},{"id":809627,"name":"Nava Suthepakul","orcid":null,"position":32,"is_corresponding":false},{"id":615730,"name":"Johnstone Tcheou","orcid":"0000-0003-2733-4687","position":33,"is_corresponding":false},{"id":809628,"name":"Narumon Thantamnu","orcid":null,"position":34,"is_corresponding":false},{"id":809629,"name":"Sompone Theerasurakarn","orcid":null,"position":35,"is_corresponding":false},{"id":429454,"name":"Steven Tran","orcid":null,"position":36,"is_corresponding":false},{"id":809630,"name":"Thanakrit Vilasmongkolchai","orcid":null,"position":37,"is_corresponding":false},{"id":809057,"name":"Jessica A. White","orcid":"0000-0003-1081-9522","position":38,"is_corresponding":false},{"id":1489,"name":"Adolfo Garcı́a-Sastre","orcid":"0000-0002-6551-1827","position":39,"is_corresponding":false},{"id":234854,"name":"Peter Palese","orcid":"0000-0002-0337-5823","position":40,"is_corresponding":false},{"id":103779,"name":"Florian Krammer","orcid":"0000-0003-4121-776X","position":41,"is_corresponding":false},{"id":809631,"name":"Kittisak Poopipatpol","orcid":null,"position":42,"is_corresponding":false},{"id":809632,"name":"Ponthip Wirachwong","orcid":null,"position":43,"is_corresponding":false},{"id":809633,"name":"Richard Hjorth","orcid":null,"position":44,"is_corresponding":false},{"id":552202,"name":"Bruce L. Innis","orcid":"0000-0002-1753-7248","position":45,"is_corresponding":false},{"id":392405,"name":"Punnee Pitisuttithum","orcid":"0000-0003-3215-2183","position":0,"is_corresponding":true}],"reference_count":23,"raw_metadata":null,"created_at":"2026-07-18T23:52:51.201033Z","pmid":"34580673","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}